American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Jan 2008
Randomized Controlled Trial Multicenter Study Comparative StudyThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
Exacerbations are key drivers of morbidity and mortality in chronic obstructive pulmonary disease (COPD). ⋯ We found no difference in exacerbation rate between salmeterol/fluticasone propionate and tiotropium. More patients failed to complete the study while receiving tiotropium. A small statistically significant beneficial effect was found on health status, with an unexpected finding of lower deaths in salmeterol/fluticasone propionate-treated patients. Clinical trial registered with www.clinicaltrials.gov (NCT 00361959).
-
Am. J. Respir. Crit. Care Med. · Jan 2008
Randomized Controlled Trial Multicenter StudyBUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease lacking effective treatment. ⋯ Bosentan treatment in patients with IPF did not show superiority over placebo on 6MWD. A trend in delayed time to death or disease progression, and improvement in QOL, was observed with bosentan. The more pronounced treatment effect in patients with biopsy-proven IPF warrants further investigation. Clinical trial registered with www.clinicaltrials.gov (NCT 00071461).
-
Am. J. Respir. Crit. Care Med. · Jan 2008
Randomized Controlled Trial Multicenter StudyBronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.
The presence of inflammatory cells on bronchoalveolar lavage is often used to predict disease activity and the need for therapy in systemic sclerosis-associated interstitial lung disease. ⋯ The presence of an abnormal lavage in the Scleroderma Lung Study defined patients with more advanced interstitial lung disease but added no additional value to physiologic and computed tomography findings as a predictor of progression or treatment response. Clinical trial registered with www.clinicaltrials.gov (NCT 000004563).